What is KYNB's 12-month stock price target?

Kyntra Bio Inc. (KYNB) carries a 12-month consensus base price target of $4.04 (-11.6% from $4.57), with a bull-case target of $11.96 and a bear-case floor of $3.15.

Stock Ratings / Health Care / KYNB / forecast

ACTU (35) AKTX (37) COCP (36) MCRB (40) ⌘ Pro Terminal →

Kyntra Bio Inc. (KYNB) 12-Month Stock Forecast & Price Target Cone

Q: Is KYNB stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates KYNB E (Strong Sell — SELL) with an RQD Confidence score of 32/100.

$4.57 -1.72% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.55

Kyntra Bio Inc. (KYNB) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $18.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KYNB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Kyntra Bio Inc. (NASDAQ: KYNB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $4.57 (-1.72% 1D, market cap $18.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, KYNB ranks #736 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KYNB compare to ACTU and AKTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, ACTU (Actuate Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M) and AKTX (Akari Therapeutics plc ADS) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KYNB?

▼

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.55 (-0.50%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KYNB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY KYNB SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (22% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.87-10.1% Next Q

Q2 (-2Q)

Grade E$5.28-14.8% Next Q

Q3 (-1Q)

Grade E$4.50+1.6% Next Q

Current

Grade E$4.57-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KYNB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KYNB currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.56) and Max Pain ($4.80) forces dealer call-delta covering toward $11.96.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KYNB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KYNB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your KYNB Position Size: $10,000

Shares at $4.57: 2188.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.15

$6,893

$-3,107 (-31.1%)

12M Consensus BaseTarget $4.04

$8,840

$-1,160 (-11.6%)

12M Bull Case BreakoutTarget $11.96

$26,171

+$16,171 (+161.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$11	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYNB)

✓Walkthrough of KYNB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KYNB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.53%📐 HORIZONTAL RANGE

2026-11-03O $4.65H $4.65L $4.57C $4.57VOL 24.4K

RES: $9.18SUP: $4.13SMA50: $6.56SMA200: $7.06

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYNB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYNB Butterfly Map → + Track KYNB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KYNB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYNB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KYNB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYNB)

Health Care Rank #736 of 1016 ⚔️ ACTU vs KYNB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KYNB vs. ACTU, AKTX, COCP, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kyntra Bio Inc. (KYNB) ranks #736 by composite RQD confidence (32/100, grade E) and #835 by equity capitalization ($18.5M). Within this direct 5-issuer industry benchmark cohort, KYNB leads on earnings valuation at N/A trailing P/E, while KYNB leads on capital efficiency and profitability with -35.0% ROIC and 91.4% gross margin. MCRB currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with KYNB at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KYNB ACTIVE Kyntra Bio Inc.	E	32/100	—	91.4%	-35.0%	-1.72%	$18.5M	Benchmark Subject
ACTU Actuate Therapeutics Inc.	D-	35/100	—	—	-35.0%	-9.68%	$18.4M	/actu-vs-kynb →
AKTX Akari Therapeutics plc ADS	D-	37/100	—	—	-35.0%	+3.00%	$18.8M	/aktx-vs-kynb →
COCP Cocrystal Pharma Inc.	D-	36/100	—	—	-35.0%	+1.53%	$19.2M	/cocp-vs-kynb →
MCRB Seres Therapeutics Inc.	D-	40/100	—	—	-35.0%	-9.23%	$17.8M	/mcrb-vs-kynb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921299

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported GAAP revenue of $6.4M (-78.3% vs. FY2024 revenue of $29.6M , and -86.2% cumulative change since FY2023) , GAAP net income of $183.5M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+96.5% YoY). On the balance sheet, KYNB closed FY2025 with $119.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.4M	$183.5M	-$4.8M	-$4.8M	$119.6M	—
FY2024 (FY)	2024-12-31	$29.6M	-$47.6M	-$138.0M	-$138.3M	$214.5M	—
FY2023 (FY)	2023-12-31	$46.8M	-$284.2M	-$315.0M	-$315.0M	—	—

3. KYNB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KYNB compare to ACTU and AKTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KYNB?

Where is KYNB trading relative to its 50-day, 200-day, and 52-week technical levels?

KYNB last traded at $4.57 (-1.72% on volume of 24,430 shares), positioning the stock -30.34% below its 50-day simple moving average ($6.56) and -35.27% below its 200-day simple moving average ($7.06). Across its 52-week range of $4.32 to $11.39, KYNB sits at the 3.5% percentile with a 14-day RSI of 28.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.00 to $5.14).

Direct Sub-Reports: KYNB RQD Cockpit KYNB 12M Forecast KYNB Earnings & Move KYNB Dividends & DRIP KYNB Insiders & 13F KYNB Whale Options KYNB Profit Sankey KYNB News & Why

ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KYNB — Kyntra Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, KYNB scores 32 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows:

Fundamental Cash Engine (4 / 20): Per the RQD rating, ROIC is -35% and FCF yield is 0%. This is the weakest pillar, indicating the business is not currently generating returns on capital or free cash flow to shareholders.
Whale 13F Flow (3 / 20): Per the RQD rating, this pillar reflects institutional accumulation and options positioning. It is the lowest-scoring pillar, suggesting limited supportive institutional signal in the source data.
Insider Conviction (7 / 20): Per the RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow.
Macro Regime Fit (6 / 20): Per the RQD rating, beta is 1.0 with sector sensitivity noted. This pillar gives no particular defensive or regime-driven advantage.
Forensic Balance Sheet (12 / 20): Per the RQD rating, Altman Z is 2.5, Piotroski F is 4/9, and Debt/Equity is 0.5. This is the strongest pillar, but still only moderate.

For a prospective investor, the pillar profile points to a company whose core economics are currently negative, with thin institutional and insider support. The forensic balance sheet is the main mitigating factor, but it does not offset weak cash generation. The grade reflects a risk-dominant picture; the analysis is educational and not personalized financial advice.

Business

Kyntra Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 91.4%, indicating a high gross margin profile. Specific product lines, customer segments, and revenue mechanics are —

Recent Catalysts & News Wire Analysis

Per the recent news wire, the dominant catalysts are governance and listing-related:

Multiple reports cover a Nasdaq delisting notice and a company appeal of the listing decision, flagged as yellow-light market wire items.
Multiple outlets report that Maxim initiated coverage with a Buy rating and a $35 price target, which stands sharply above the current price of $4.65 and should be weighed against the delisting risk.
A report notes a director received 14,000 stock options at a $6.50 exercise price.

Risk watch items: the delisting notice and appeal status, the wide gap between the Maxim target and the current price, and the revenue decline. The Butterfly supply-chain graph reports no proprietary signals or links.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain status is NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlation mappings are therefore — A prospective investor should note that any second-order ripple analysis cannot be derived from the provided graph; the most material second-order risk visible in the sources is the listing-status question, which could affect liquidity and institutional eligibility.

Analyst View & Smart Money Ownership

Per the analyst data, the source reports NONE for analyst coverage. The news wire separately references a Maxim initiation with a Buy rating and $35 price target, but this is not reflected in the structured analyst data field. Per the holders data, the source reports NONE, so 13F institutional, SEC Form 4 insider, and Congressional trade detail are —

Open Questions

What is the outcome of the Nasdaq delisting appeal, and what is the timeline for a decision?
What drove the FY 2025 net income of $183.5M when operating income was $-45.9M, and is this a one-time item?
What is the composition of total debt, given that debt is N/A across all reported periods?
What are the company's specific products, approved indications, and revenue sources behind the declining top line?
Is the Maxim $35 price target supported by a documented basis, and how does it reconcile with the $4.65 price?

KYNB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kyntra Bio Inc. (KYNB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KYNB Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 19h ago

Kyntra Bio Received Notice of Delisting

TradingView report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 22h ago

Kyntra Bio Faces Nasdaq Delisting, Appeals Listing Decision

The Globe and Mail report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Maxim Initiates Coverage on Kyntra Bio With Buy Rating, $35 Price Target

Yahoo Finance report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

Maxim Group Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35

Moomoo report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A director receives 14,000 Kyntra Bio (KYNB) stock options with a $6.50 exercise price.

Stock Titan report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Maxim Group initiates Kyntra Bio stock coverage with buy rating By Investing.com

Investing.com UK report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Kyntra Bio stock: Maxim initiates coverage for Kyntra Bio stock at USD 35.00

ad-hoc-news.de report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 1d ago

Form 4 Kyntra Bio Inc For: 6 October By Investing.com

Investing.com UK report covering Kyntra Bio Inc. (KYNB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KYNB Bull vs. Bear Conversation Board — What's Your Call at $4.57?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KYNB 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 Options Flow Specialist 🐂 BULLISH 🎯 Target: $5.39 (+17.9%)

📌 Pinned Debate

Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.

Here is why I am bullish on KYNB here at $4.57: Maxim initiated coverage with a Buy rating and a $35 price target, and the company reports a 91.4% gross margin.. Compare KYNB's -60.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $4.34 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — KYNB's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.56 (-22.1%)

Spot @ $4.57

Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.

I respect the product at Kyntra Bio Inc., but the stock at $4.57 is a different story. Revenue fell from $46.8M in FY 2023 to $6.4M in FY 2025 while ROIC sits at -35% and the company faces a Nasdaq delisting notice.. FCF yield is 0.0% and RQD sits at 32/100 (E) — why pay up here when you can wait for next quarter's numbers?